Innovation needed in weight-loss medications

Shortages of diabetes medication, Ozempic (semaglutide), fueled by off-label prescribing of it as a weight-loss treatment, highlight the need for new drugs to tackle obesity.   With supplier, Novo Nordisk reporting that supplies of Ozempic will not be available in Australia until April, patients with type 2 diabetes who use the medication to help manage